Indirubin-5-sulfonic acid sodium salt is a cyclin-dependent kinase (CDK) inhibitor, in particular CDK1/cyclin B (IC50 = 55 nM), CDK2/cyclin A (IC50 = 35 nM), CDK2/cyclin E (IC50 = 150 nM), CDK4/cyclin D1(IC50 = 300 nM), and CDK5/p35 (IC50 = 65 nM), with additional inhibitory activity against GSK-3β.
1. Hoessel, R., et al., 1999. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature cell biology. 1(1): 60-7. PMID: 10559866
2. Leclerc, S., et al., 2001. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? The Journal of biological chemistry. 276(1): 251-60. PMID: 11013232
3. Marko, D., et al., 2001. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. British journal of cancer. 84(2): 283-9. PMID: 11161389
4. Davies, T G., et al., 2001. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure (London, England : 1993). 9(5): 389-97. PMID: 11377199
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.